Labcorp® Plasma Detect™ Clinical Studies Featured in Nature Medicine and Clinical Cancer Research
Labcorp (NYSE: LH) announced that Labcorp Plasma Detect, a tumor‑informed blood assay for detecting molecular residual disease (MRD) from circulating tumor DNA, was featured in two peer‑reviewed studies published Nov 19, 2025.
A Nature Medicine study in diffuse pleural mesothelioma reported that both neoadjuvant immune regimens were safe, enabled most patients to undergo surgery, and that Plasma Detect tracked early disease progression and predicted long‑term progression‑free survival. A Clinical Cancer Research study found that lymph drain fluid collected 24 hours after head and neck cancer surgery contained more tumor DNA than simultaneous plasma and that lymph‑based testing identified residual cancer missed by pathology.
Labcorp (NYSE: LH) ha annunciato che Labcorp Plasma Detect, un test ematico informato dai tumori per rilevare la malattia residua molecolare (MRD) dal DNA tumorale circolante, è stato oggetto di due studi peer‑review pubblicati il 19 novembre 2025.
Un studio su Nature Medicine sul mesotelioma diffuso della pleura ha riportato che entrambi i regimi immunoterapici neoadiuvanti erano sicuri, hanno permesso alla maggior parte dei pazienti di sottoporsi all'intervento chirurgico e che Plasma Detect ha monitorato la progressione precoce della malattia e previsto una sopravvivenza libera da progressione a lungo termine. Un studio su Clinical Cancer Research ha rilevato che il fluido di drenaggio linfatico raccolto 24 ore dopo l'intervento per tumore della testa e del collo conteneva più DNA tumorale rispetto al plasma contemporaneo e che i test basati sui linfonodi hanno identificato tumori residui non rilevati dalla patologia.
Labcorp (NYSE: LH) anunció que Labcorp Plasma Detect, una prueba sanguínea informada por tumores para detectar la enfermedad residual molecular (MRD) a partir del ADN tumoral circulante, fue presentada en dos estudios revisados por pares publicados el 19 de noviembre de 2025.
Un estudio de Nature Medicine sobre mesotelioma difuso de pleura informó que ambos regímenes inmunitarios neoadyuvantes eran seguros, permitieron que la mayoría de los pacientes se sometieran a cirugía y que Plasma Detect rastreó la progresión temprana de la enfermedad y predijo la supervivencia libre de progresión a largo plazo. Un estudio de Clinical Cancer Research encontró que el líquido de drenaje linfático recogido 24 horas después de la cirugía de cáncer de cabeza y cuello contenía más ADN tumoral que el plasma simultáneo y que las pruebas basadas en la linfa identificaron cáncer residual que pasó desapercibido en la patología.
Labcorp (NYSE: LH)가 Labcorp Plasma Detect가 순환 종양 DNA에서 분자 잔류 질환(MRD)을 탐지하기 위한 종양 정보 기반 혈액 검사로, 2025년 11월 19일 발표된 두 편의 동료 심사 연구에 실렸다고 발표했습니다.
Nature Medicine의 diffuse pleural mesothelioma 연구는 두 가지 네오아주vant 면역 요법이 안전했고, 대부분의 환자가 수술을 받을 수 있게 했으며, Plasma Detect가 조기 질병 진행을 추적하고 장기 무진행 생존을 예측했다고 보고했습니다. Clinical Cancer Research의 연구는 두경부암 수술 후 24시간에 수집된 림프 배액액이 동시 혈장보다 더 많은 종양 DNA를 함유했고 림프 기반 검사가 병리학에서 놓친 잔여 암을 식별했다고 밝혔습니다.
Labcorp (NYSE: LH) a annoncé que Labcorp Plasma Detect, un test sanguin informé par la tumeur pour détecter la maladie résiduelle moléculaire (MRD) à partir de l'ADN tumoral circulant, a été présenté dans deux études évaluées par des pairs publiées le 19 novembre 2025.
Une étude dans Nature Medicine sur le mesothéliome pleural diffus a rapporté que les deux régimes immunitaires néoadjuvants étaient sûrs, ont permis à la plupart des patients de subir une chirurgie et que Plasma Detect a suivi la progression précoce de la maladie et prédit une survie sans progression à long terme. Une étude dans Clinical Cancer Research a révélé que le fluide de drainage lymphatique prélevé 24 heures après une chirurgie pour cancer de la tête et du cou contenait plus d'ADN tumoral que le plasma simultané et que les tests basés sur la lymphe ont identifié un cancer résiduel non détecté par la pathologie.
Labcorp (NYSE: LH) gab bekannt, dass Labcorp Plasma Detect, ein tumorinformierter Bluttest zum Nachweis der molekularen residuellen Erkrankung (MRD) aus zirkulierender Tumor-DNA, in zwei peer‑reviewten Studien enthalten ist, veröffentlicht am 19. November 2025.
Eine Studie in Nature Medicine zum diffusen pleuralen Mesotheliom berichtete, dass beide neoadjuvante Immunregime sicher waren, die meisten Patienten operiert werden konnten und dass Plasma Detect den frühen Krankheitsverlauf verfolgte und das langfristige progressionsfreie Überleben vorhersagte. Eine Studie in Clinical Cancer Research ergab, dass die Lymphabflussflüssigkeit, die 24 Stunden nach einer Kopf- und Halskrebs-Operation gesammelt wurde, mehr Tumor-DNA enthielt als das gleichzeitige Plasma und dass lymph-basierte Tests verbleibende Krebszellen identifizierten, die von der Pathologie übersehen wurden.
Labcorp (NYSE: LH) أعلنت أن Labcorp Plasma Detect، اختبار دمّ معلوماتي قائم على الورم لاكتشاف المرض المتبقي الجزيئي (MRD) من DNA الورمي المنسوخ، أُدرج في دراستين محكّمتين نُشرتا في 19 نوفمبر 2025.
وجدت دراسة في Nature Medicine حول الورم النقّالي الجنبي المنتشر أن كلا النظامين المناعيين قبل الجراحة كانا آمنين، سمحا لمعظم المرضى بإجراء الجراحة، وأن Plasma Detect تتبّع التقدم المرضي المبكر وتوقّعت بقاء خالٍ من التقدم المرضي على المدى الطويل. كما وجدت دراسة في Clinical Cancer Research أن سائل التصريف اللمفي الذي جُمِعَ بعد 24 ساعة من جراحة سرطان الرأس والرقبة كان يحتوي على مزيد من DNA الورم مقارنةً بالدم البلازما في آن واحد، وأن الاختبارات المستندة إلى العقدة اللمفاوية حددت سرطانًا residual لم تُكتشفه Patology.
- Nature Medicine (Nov 19, 2025) showed Plasma Detect tracked early progression and predicted progression‑free survival
- Clinical Cancer Research (Nov 19, 2025) found lymph drain fluid had more tumor DNA than plasma 24 hours post‑surgery
- Both neoadjuvant immune regimens were reported safe and allowed most patients to proceed to surgery
- Studies reported findings but did not disclose patient‑level survival rates or quantitative effect sizes
- No commercial guidance, reimbursement impact, or timing for clinical rollout was provided
Insights
Peer‑reviewed studies show Labcorp Plasma Detect reliably detects MRD and may guide perioperative and post‑surgical decisions.
Labcorp Plasma Detect is a tumor‑informed, blood‑based ctDNA assay that the studies used to track molecular residual disease. One Nature Medicine report linked ctDNA changes to early progression and to long‑term progression‑free survival after neoadjuvant immune therapy in diffuse pleural mesothelioma, while a Clinical Cancer Research paper showed lymph drain fluid collected 24 hours post‑surgery contained more tumor DNA than same‑time plasma and identified residual disease missed by pathology.
These results describe two distinct clinical mechanisms: perioperative ctDNA monitoring to signal early progression and possible durable response after dual checkpoint blockade, and immediate post‑surgical lymph fluid testing to reveal locoregional residual disease. Both uses rely on the assay’s ability to detect tumor‑informed variants in low‑volume samples and on timing of sampling relative to therapy and surgery, which remain critical dependencies.
Cautious interpretation is warranted because the content reports study findings without effect sizes, cohort sizes, statistical thresholds, or regulatory outcomes. Watch for published metrics such as sensitivity, specificity, positive predictive value, cohort size, and follow‑up duration, and for any prospective trials or guideline endorsements that validate utility in larger populations over the next 12–24 months.
Studies demonstrate Labcorp Plasma Detect MRD Technology can inform treatment strategies and advance cancer research
New Study Offers Hope for Rare and Aggressive Cancer
A study published in Nature Medicine provides encouraging results for patients with diffuse pleural mesothelioma (DPM), a rare and deadly cancer often linked to asbestos exposure. Researchers evaluated two immune-based treatment regimens given before surgery. Both approaches proved safe and enabled most patients to proceed with surgery. Notably, patients receiving neoadjuvant dual immune checkpoint blockade showed signals of durable clinical response. The study also demonstrated that Labcorp Plasma Detect can track early disease progression and predict long-term, progression-free survival. These findings suggest that perioperative immunotherapy combined with ctDNA monitoring may help shape new, more effective treatment strategies.
Post-Surgical Monitoring Breakthrough in Head and Neck Cancer
A study published in Clinical Cancer Research found that fluid collected from surgical drains after head and neck cancer surgery contains more tumor DNA than peripheral blood samples taken at the same time. Using Labcorp Plasma Detect, researchers compared lymph fluid to plasma collected 24 hours post-surgery and confirmed that lymph-based testing effectively identified residual cancer, particularly in patients with locoregional recurrence, signaling risk in patients who might otherwise go undetected by traditional pathology methods. These findings suggest that incorporating lymph fluid testing immediately after surgery, alongside plasma monitoring, could enable faster, more accurate decisions about follow-up treatment and improve outcomes for patients with HPV-independent head and neck cancer.
"These studies underscore the clinical utility of Labcorp Plasma Detect in advancing cancer research," said Shakti Ramkissoon, M.D., Ph.D., MBA, vice president and medical lead for oncology at Labcorp. "By demonstrating its ability to track early disease progression, predict long-term outcomes, and identify residual cancer in challenging contexts, our MRD technology provides critical insights that can inform future treatment strategies and improve understanding of tumor biology."
For more information on Labcorp's MRD portfolio, visit https://oncology.labcorp.com.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than
View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-plasma-detect-clinical-studies-featured-in-nature-medicine-and-clinical-cancer-research-302620138.html
SOURCE Labcorp
FAQ
What did Labcorp announce about Plasma Detect on November 19, 2025 (LH)?
How did the Nature Medicine study on Nov 19, 2025 use Plasma Detect in diffuse pleural mesothelioma (LH)?
What did Clinical Cancer Research report about lymph fluid testing with Plasma Detect (LH) on Nov 19, 2025?
Does the Nov 19, 2025 Labcorp announcement (LH) include commercial or financial guidance for Plasma Detect?
What implications do the Nov 19, 2025 studies have for patients and clinicians using Plasma Detect (LH)?
